Alkahest to Present New Data from Phase 2a Study in Mild-to-Moderate Alzheimer’s Disease at the Clinical Trials in Alzheimer’s Disease (CTAD) Conference
SAN CARLOS, Calif., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Alkahest Inc., a clinical stage biotechnology company focused on discovering and developing transformative therapies to treat age-related diseases, today announced an oral presentation of data from its phase 2a study ALK6019-201 in mild-to-moderate Alzheimer’s Disease at the 12th Clinical Trials on Alzheimer’s Disease from December 4 – 7, 2019 in San Diego. Presentation details can be found below.
Oral presentation:
Title: A Phase 2 trial of GRF6019 in mild-to-moderate Alzheimer’s Disease
Presenter: Jonas Hannestad, vice president of clinical development at Alkahest
Session: Oral Communications Sessions 35
Date: Saturday, December 7, 2019
Start Time: 2:00 pm PST
Location: Hilton Bayfront San Diego; Indigo Ballroom ABCEFG
About Study ALK6019-201
The ALK6019-201 study is a completed Phase 2a clinical trial, designed to evaluate the safety, tolerability, and potential therapeutic effects of GRF6019 in patients with mild-to-moderate Alzheimer’s disease over a six-month period. Subjects were randomized and treated intravenously with 100 mL or 250 mL of GRF6019 for five consecutive days during Week 1 and again for five consecutive days during Week 13, with a treatment-free interval of 11 weeks following each dose.
About GRF6019 and GRF6021
Alkahest and clinical and development partner Grifols are studying GRF6019 and GRF6021 for the treatment of age-related diseases. GRF6019 and GRF6021, proprietary plasma fractions, are developed and provided by Grifols. In animal models, these plasma fractions enhance neurogenesis, improve age-related deficits in learning and memory, and reduce neuroinflammation. Phase 2 clinical trials with GRF6019 and GRF6021 are ongoing in severe Alzheimer’s disease, Parkinson’s disease, and post-operative recovery, with other indications being explored.
About Alkahest
Alkahest is a clinical stage biopharmaceutical company dedicated to discovering and developing treatments for neurodegenerative and age-related diseases with transformative therapies targeting the aging plasma proteome. The Alkahest pipeline includes multiple therapeutic candidates ranging from selected plasma fractions to protein-targeted interventions which aim to slow the detrimental biological processes of aging. Alkahest is developing novel plasma-based therapies in collaboration with Grifols, a global healthcare company and leading producer of plasma therapies. For further information see www.alkahest.com or follow us on Twitter @AlkahestInc.
Contact Information
Elizabeth Jeffords
Chief Commercial & Strategy Officer
Alkahest, Inc.
ejeffords@alkahest.com
Media Contact
Michael Tattory
LifeSci Public Relations
mtattory@lifescipublicrelations.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
